Imagine a world without cancer

J 2014

Imagine a world without cancer

BRUCHER, Björn LDM, Gary LYMAN, Richard van HILLEGERSBERG, Raphael E. POLLOCK, Florian LORDICK et. al.

Základní údaje

Originální název

Imagine a world without cancer

Autoři

BRUCHER, Björn LDM (840 Spojené státy), Gary LYMAN (840 Spojené státy), Richard van HILLEGERSBERG (528 Nizozemské království), Raphael E. POLLOCK (840 Spojené státy), Florian LORDICK (276 Německo), Han-Kwang YANG (410 Korejská republika), Toshikazu USHIJIMA (392 Japonsko), Khay-Guan YEOH (702 Singapur), Tomáš SKŘIČKA (203 Česká republika, garant, domácí), Wojciech POLKOWSKI (616 Polsko), Grzegorz WALLNER (616 Polsko), Vic VERWAAL (528 Nizozemské království), Alfredo GAROFALO (380 Itálie), Domenico D´UGO (380 Itálie), Franco ROVIELLO (380 Itálie), Hans-Ulrich STEINAU (276 Německo), Timothy J. WALLACE (840 Spojené státy), Martin DAUMER (276 Německo), Nitah MAIHLE (840 Spojené státy), Thomas J. REID (840 Spojené státy), Michel DUCREUX (250 Francie), Yuko KITAGAWA (392 Japonsko), Alexander KNUTH (634 Katar), Bruno ZILBERSTEIN (76 Brazílie), Scott R. STEELE (840 Spojené státy) a Ijaz S. JAMALL (840 Spojené státy)

Vydání

BMC Cancer, London, BioMed Central, 2014, 1471-2407

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30200 3.2 Clinical medicine

Stát vydavatele

Velká Británie a Severní Irsko

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 3.362

Kód RIV

RIV/00216224:14110/14:00077732

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.1186/1471-2407-14-186

UT WoS

000333422100002

Klíčová slova anglicky

Cancer; Carcinogenesis; Multimodal therapy; Cancer classification; Personalized anticancer therapy; Individualized anticancer therapy

Štítky

EL OK

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 11. 12. 2014 15:20, Soňa Böhmová

Anotace

V originále

Since the "War on Cancer" was declared in 1971, the United States alone has expended some $300 billion on research, with a heavy focus on the role of genomics in anticancer therapy. Voluminous data have been collected and analyzed. However, in hindsight, any achievements made have not been realized in clinical practice in terms of overall survival or quality of life extended. This might be justified because cancer is not one disease but a conglomeration of multiple diseases, with widespread heterogeneity even within a single tumor type. Discussion: Only a few types of cancer have been described that are associated with one major signaling pathway. This enabled the initial successful deployment of targeted therapy for such cancers. However, soon after this targeted approach was initiated, it was subverted as cancer cells learned and reacted to the initial treatments, oftentimes rendering the treatment less effective or even completely ineffective. During the past 30 plus years, the cancer classification used had, as its primary aim, the facilitation of communication and the exchange of information amongst those caring for cancer patients with the end goal of establishing a standardized approach for the diagnosis and treatment of cancers. This approach should be modified based on the recent research to affect a change from a service-based to an outcome-based approach. The vision of achieving long-term control and/or eradicating or curing cancer is far from being realized, but not impossible. In order to meet the challenges in getting there, any newly proposed anticancer strategy must integrate a personalized treatment outcome approach. This concept is predicated on tumor-and patient-associated variables, combined with an individualized response assessment strategy for therapy modification as suggested by the patient's own results. As combined strategies may be outcome-orientated and integrate tumor-, patient-as well as cancer-preventive variables, this approach is likely to result in an optimized anticancer strategy. Summary: Herein, we introduce such an anticancer strategy for all cancer patients, experts, and organizations: Imagine a World without Cancer.

Citovat

BRUCHER, Björn LDM, Gary LYMAN, Richard van HILLEGERSBERG, Raphael E. POLLOCK, Florian LORDICK, Han-Kwang YANG, Toshikazu USHIJIMA, Khay-Guan YEOH, Tomáš SKŘIČKA, Wojciech POLKOWSKI, Grzegorz WALLNER, Vic VERWAAL, Alfredo GAROFALO, Domenico D´UGO, Franco ROVIELLO, Hans-Ulrich STEINAU, Timothy J. WALLACE, Martin DAUMER, Nitah MAIHLE, Thomas J. REID, Michel DUCREUX, Yuko KITAGAWA, Alexander KNUTH, Bruno ZILBERSTEIN, Scott R. STEELE a Ijaz S. JAMALL. Imagine a world without cancer. BMC Cancer. London: BioMed Central, 2014, roč. 14, č. 186, s. 1-8. ISSN 1471-2407. Dostupné z: https://dx.doi.org/10.1186/1471-2407-14-186.

@article{1212655,
   author = {Brucher, Björn LDM and Lyman, Gary and Hillegersberg, Richard van and Pollock, Raphael E. and Lordick, Florian and Yang, HanandKwang and Ushijima, Toshikazu and Yeoh, KhayandGuan and Skřička, Tomáš and Polkowski, Wojciech and Wallner, Grzegorz and Verwaal, Vic and Garofalo, Alfredo and D´Ugo, Domenico and Roviello, Franco and Steinau, HansandUlrich and Wallace, Timothy J. and Daumer, Martin and Maihle, Nitah and Reid, Thomas J. and Ducreux, Michel and Kitagawa, Yuko and Knuth, Alexander and Zilberstein, Bruno and Steele, Scott R. and Jamall, Ijaz S.},
   article_location = {London},
   article_number = {186},
   doi = {http://dx.doi.org/10.1186/1471-2407-14-186},
   keywords = {Cancer; Carcinogenesis; Multimodal therapy; Cancer classification; Personalized anticancer therapy; Individualized anticancer therapy},
   language = {eng},
   issn = {1471-2407},
   journal = {BMC Cancer},
   title = {Imagine a world without cancer},
   volume = {14},
   year = {2014}
}

TY  - JOUR
ID  - 1212655
AU  - Brucher, Björn LDM - Lyman, Gary - Hillegersberg, Richard van - Pollock, Raphael E. - Lordick, Florian - Yang, Han-Kwang - Ushijima, Toshikazu - Yeoh, Khay-Guan - Skřička, Tomáš - Polkowski, Wojciech - Wallner, Grzegorz - Verwaal, Vic - Garofalo, Alfredo - D´Ugo, Domenico - Roviello, Franco - Steinau, Hans-Ulrich - Wallace, Timothy J. - Daumer, Martin - Maihle, Nitah - Reid, Thomas J. - Ducreux, Michel - Kitagawa, Yuko - Knuth, Alexander - Zilberstein, Bruno - Steele, Scott R. - Jamall, Ijaz S.
PY  - 2014
TI  - Imagine a world without cancer
JF  - BMC Cancer
VL  - 14
IS  - 186
SP  - 1-8
EP  - 1-8
PB  - BioMed Central
SN  - 14712407
KW  - Cancer
KW  - Carcinogenesis
KW  - Multimodal therapy
KW  - Cancer classification
KW  - Personalized anticancer therapy
KW  - Individualized anticancer therapy
N2  - Since the "War on Cancer" was declared in 1971, the United States alone has expended some $300 billion on research, with a heavy focus on the role of genomics in anticancer therapy. Voluminous data have been collected and analyzed. However, in hindsight, any achievements made have not been realized in clinical practice in terms of overall survival or quality of life extended. This might be justified because cancer is not one disease but a conglomeration of multiple diseases, with widespread heterogeneity even within a single tumor type. Discussion: Only a few types of cancer have been described that are associated with one major signaling pathway. This enabled the initial successful deployment of targeted therapy for such cancers. However, soon after this targeted approach was initiated, it was subverted as cancer cells learned and reacted to the initial treatments, oftentimes rendering the treatment less effective or even completely ineffective. During the past 30 plus years, the cancer classification used had, as its primary aim, the facilitation of communication and the exchange of information amongst those caring for cancer patients with the end goal of establishing a standardized approach for the diagnosis and treatment of cancers. This approach should be modified based on the recent research to affect a change from a service-based to an outcome-based approach. The vision of achieving long-term control and/or eradicating or curing cancer is far from being realized, but not impossible. In order to meet the challenges in getting there, any newly proposed anticancer strategy must integrate a personalized treatment outcome approach. This concept is predicated on tumor-and patient-associated variables, combined with an individualized response assessment strategy for therapy modification as suggested by the patient's own results. As combined strategies may be outcome-orientated and integrate tumor-, patient-as well as cancer-preventive variables, this approach is likely to result in an optimized anticancer strategy. Summary: Herein, we introduce such an anticancer strategy for all cancer patients, experts, and organizations: Imagine a World without Cancer.
ER  -

BRUCHER, Björn LDM, Gary LYMAN, Richard van HILLEGERSBERG, Raphael E. POLLOCK, Florian LORDICK, Han-Kwang YANG, Toshikazu USHIJIMA, Khay-Guan YEOH, Tomáš SKŘIČKA, Wojciech POLKOWSKI, Grzegorz WALLNER, Vic VERWAAL, Alfredo GAROFALO, Domenico D´UGO, Franco ROVIELLO, Hans-Ulrich STEINAU, Timothy J. WALLACE, Martin DAUMER, Nitah MAIHLE, Thomas J. REID, Michel DUCREUX, Yuko KITAGAWA, Alexander KNUTH, Bruno ZILBERSTEIN, Scott R. STEELE a Ijaz S. JAMALL. Imagine a world without cancer. \textit{BMC Cancer}. London: BioMed Central, 2014, roč.~14, č.~186, s.~1-8. ISSN~1471-2407. Dostupné z: https://dx.doi.org/10.1186/1471-2407-14-186.

Podrobný výpis o publikaci